M·CAM releases Patently Obvious® on the PTAB Review of Allergan Patents

Date:  Fri, 2015-04-10

CHARLOTTESVILLE, VA April 10, 2015- M·CAM released its Patently Obvious® on the PTAB Review of Allergan Patents.

Multinational pharmaceutical firm Allergan is facing a patent review challenge before the USPTO’s Patent Trial and Appeal Board (PTAB). The inter partes review (IPR), brought by New York-based hedge fund Ferrum Ferro Capital, challenges the validity of one of Allergan’s patents that protects the glaucoma drug Combigan®. As we reported in our last Patently Obvious®, released on March 19, this and other IPR cases are being brought as part of a new investment strategy that aims to profit from patent invalidations against large pharmaceutical companies.

M·CAM’s Patently Obvious® is a report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.

M·CAM is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The M·CAM Patently Obvious® report on the PTAB Review of Allergan Patents can be found HERE.